# Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

> **NCT04525209** · — · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT04525209
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04525209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04525209, "Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04525209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*